Kinney Drugs’ Post

And Another One!!! Employers, please act! These lawsuits and reports documenting the Big PBM's business practices that lead to increased cost could cost you with CAA sanctions from the Dept. of Labor and litigation like J&J and Wells Fargo (remember all corporate officers or personally liable as well as the company). Please contact a "non-conflicted" pharmacy benefit consultant to discuss how you can eliminate or at least reduce your exposure. Please contact me if you would like a list of "non-conflicted" pharmacy benefit consultants. Please realize that if you are using one of the big consulting firms that are actually "paid agents" for your PBM due to the 4 - 10+ times more money your PBM is paying your consultant than you are paying your consultant, they cannot recommend moving from your current exposure without jeopardizing those revenues from your PBM. If you you would like to discuss our fiduciary PBM or independent utilization management services, please contact me @ mmincy@us-rxcare.com The time to act is now! #CEO #COO #CFO #CHRO #Fiduciary #CAA #DoTheRightThing

In light of the challenges posed by the withholding of claims data and the potential impact on the 340B program, innovative solutions like Nuvem's holistic pharmacy management platform could play a crucial role in empowering Covered Entities to navigate these complexities effectively. By leveraging Nuvem's comprehensive solution, Covered Entities can enhance their internal data analytics capabilities, optimize pharmacy operations, and drive better patient health and financial outcomes. Nuvem's focus on empowering organizations to manage patient prescriptions holistically aligns well with the evolving landscape of healthcare regulations, offering a strategic approach to address the challenges while maximizing the benefits of the 340B program. This proactive approach could help Covered Entities mitigate the effects of restricted data access and ensure ongoing compliance with program requirements, ultimately driving positive impacts on patient care and financial performance. #nuvem #340b

Thanks, Chris Fisher, for inviting The Rx Save Card to take the 3x3x3 challenge! The Rx Save Card is the perfect solution for self-funded employers that want to access lower prescription drug costs through Mark Cuban Cost Plus Drug Company, PBC, Cash Prices and Discount Cards without needing to change #PBMs. Employers are able to meet their #ERISA #Fiduciary obligations, while reducing their prescription drug spend. Employees get many drugs for free. A true win-win! https://lnkd.in/g-shm9E3

Please feel free to share Nick Hunter's short video on how people can use Pharmacy First during the junior doctors' strike. #communitypharmacy #pharmacyfirst

Shocking Mass Tort News - GSK Settles Zantac Trial Case Actually this news isn't shocking at all. This is what Defendants always do. After the FDA in 2020 asked GSK and other manufacturers to remove Zantac from the market, GSK said it's product was safe and it would defend all lawsuits. 4 years later we are learning GSK's true intention. While refusing to engage in a global settlement, GSK has regularly settled every individual case right before or during trial. The lone exception was the defense pick in the prior Illinois trial that resulted in a defense verdict that GSK promoted to everyone who would listen. Right now GSK is attempting to get the DE Daubert opinion over turned while wrapping its arms around the true number of Zantac cases and its potential exposure. Expect GSK to continue to settle every individual case that makes it to trial before entering into a global settlement sometime in 2025. Now is a good time to get more Zantac cases. #joedoeslaw #masstorts #zantac

🚀 Exciting News from DemandLane! 🚀 We are proud to share we are delivering Zantac retainer packets daily, with the capability to scale as needed! 📢 Background: In 2020, the FDA requested GSK and other manufacturers to remove Zantac from the market. GSK initially claimed their product was safe and vowed to defend all lawsuits. Fast forward four years, and the reality of GSK’s strategy is becoming clear. 🔍 Current Situation:    •   GSK has avoided a global settlement, opting instead to settle individual cases right before or during trial.    •   The notable exception was a defense pick in the prior Illinois trial, which resulted in a defense verdict that GSK widely promoted.    •   GSK is now seeking to overturn the DE Daubert opinion while assessing the true number of Zantac cases and its potential exposure. 📅 Future Outlook: Expect GSK to continue settling individual cases that reach trial, with a potential global settlement anticipated sometime in 2025. ✨ Opportunity: Now is the perfect time to get more Zantac cases. Demandlane is ready to support you with scalable solutions, ensuring your clients receive the attention and resources they deserve. Let’s work together to navigate Zantac and secure the best outcomes for all affected by Zantac. Give me a shout to learn more about how we can assist your firm! 💪 #LegalTech #MassTorts #ZantacLitigation #DemandLane #ClientSupport #ScalableSolutions

TD - TARDIVE DYSKINESIA Breaking News - the FDA just approved multiple additional once a day, one pill a day, doses of Austedo XR! It’s a big deal, and important development for improving adherence and acceptability of treatment in our unfortunate patients with TD. Progress is happening so rapidly in the world! This milestone is worth celebrating. Here is a press release worth a quick review. https://lnkd.in/g3r2EAi8

The Hidden Costs of Drug Rebates With legislation like the S.1339 Pharmacy Benefit Manager Reform Act coming into play, there's increasing pressure to pass rebate dollars through to payors and, ultimately, to the members. However, there are no real beneficiaries of these rebate programs except the pharmaceutical companies. The Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) have published analyses implying that a significant chunk of rebates is used to reduce premiums and manage costs. However, eliminating drug rebates would significantly lower drug costs by removing the inflated pricing needed to account for potential rebates. The drama surrounding drug manufacturer rebates and their supposed reduction in prescription costs could rival a popular TV series. We are told that these rebates are the drug manufacturers' knights in shining armor, slashing drug costs. However, like Dorothy in 'The Wizard of Oz,' it becomes clear that it's all smoke and mirrors. These rebates inflate the costs of drugs, administrative expenses, and premiums. As public awareness grows, I hope that rebates can be phased out. My mother always said, "Nothing is free," and drug rebates are no exception. These rebates are built into the cost of medication and premiums, with employer groups and payors paying inflated prices for drugs and then having to jump through hoops to get their money back, minus the administrative costs. Everyone stands to benefit from eliminating rebates. Pharmaceutical and ‘middleman’ companies could reduce system, administrative, and labor costs, leading to lower healthcare premiums and drug prices. Payors and employer groups would no longer need to transfer their money to pharmaceutical manufacturers and then struggle to retrieve it. The bottom line is that we should let the quality of the products and health outcomes drive utilization rather than relying on marketing strategies. Imagine the billions that could be saved by eliminating artificially inflated drug prices and associated administrative costs from the healthcare ecosystem.

Today, the Big Three PBM CEOs went out of their way to justify their massive profits, which come at the expense of American businesses, their employees, and most importantly, patients. Unlike transparent PBMs, who offer their services for a simple, clear fee, the big PBMs manipulate users and disguise their prices with confusing gimmicks and hidden fees. We continue to support Chairman Comer’s work on the House Oversight Committee to bring necessary reforms to the PBM market. It is time we delink Big Three PBMs’ profits from prescription drug costs and bring transparency and relief to the American people.

Expand the SCOTUS… Justices absolutely corrupt & unaccountable… 👿Narco-Pharma what’s the difference?… Corporate crime & drug dealing unaccountable in U.S. Judiciary… #purdue #purduepharma #pharmaceuticals #oxycontin #opiods #opioidcrisis #opioidepidemic #opioidaddiction #opioidusedisorder #pharmacompanies #pharmaceuticalmanufacturing #pharmanews #pharmaindustry #pharmaindustrie #pharmacybusiness #drugaddiction #drugcrisis #greed #corruption #narco #moneylaundering #dea #drugtrafficking #drugabuse